Table 3.
Multivariable Cox regression analyses of potential risk factors for solid tumor, cardiovascular disease, and infectious disease mortalitya
| Risk factors | Solid tumors (n = 568) |
Cardiovascular disease (n = 363)b |
Infectious disease (n = 69) |
|||
|---|---|---|---|---|---|---|
| No.c | HR (95% CI) | No.c | HR (95% CI) | No.c | HR (95% CI) | |
| Sex | ||||||
| Male | 323 | 1.00 (Ref.) | 231 | 1.00 (Ref.) | 45 | 1.00 (Ref.) |
| Female | 245 | 0.88 (0.75 to 1.05) | 132 | 0.57 (0.46 to 0.71) | 24 | 0.71 (0.43 to 1.18) |
| Age at HL treatment, y | ||||||
| <25 | 165 | 1.00 (Ref.) | 102 | 1.00 (Ref.) | 17 | 1.00 (Ref.) |
| 25-34 | 197 | 0.69 (0.56 to 0.86) | 107 | 0.73 (0.55 to 0.97) | 25 | 1.47 (0.74 to 2.93) |
| 35-50 | 206 | 0.48 (0.38 to 0.61) | 154 | 0.71 (0.53 to 0.97) | 27 | 1.31 (0.61 to 2.82) |
| Supradiaphragmatic RT | ||||||
| No RT or no supradiaphragmatic RT | 66 | 1.00 (Ref.) | 21 | 1.00 (Ref.) | 8 | 1.00 (Ref.) |
| Yes | 482 | 2.02 (1.54 to 2.65) | 331 | 4.36 (2.74 to 6.94) | 60 | 2.17 (0.99 to 4.79) |
| Infradiaphragmatic RT | ||||||
| No RT or no infradiaphragmatic RT | 254 | 1.00 (Ref.) | 166 | 1.00 (Ref.) | 26 | 1.00 (Ref.) |
| Yes, no spleen | 139 | 1.46 (1.16 to 1.85) | 89 | 1.21 (0.90 to 1.63) | 19 | 1.70 (0.87 to 3.30) |
| Yes, including spleen | 155 | 1.52 (1.23 to 1.87) | 97 | 1.38 (1.06 to 1.80) | 23 | 2.81 (1.55 to 5.07) |
| Splenectomy | ||||||
| No | 367 | 1.00 (Ref.) | 224 | 1.00 (Ref.) | 38 | 1.00 (Ref.) |
| Yes | 178 | 1.02 (0.82 to 1.26) | 126 | 1.04 (0.79 to 1.36) | 29 | 2.52 (1.40 to 4.53) |
| CT | ||||||
| Anthracyclines | ||||||
| No CT or no anthracyclines | 406 | 1.00 (Ref.) | 280 | 1.00 (Ref.) | 37 | 1.00 (Ref.) |
| ≤210-g/m2 anthracycline dose | 52 | 0.87 (0.62 to 1.21) | 22 | 0.68 (0.40 to 1.14) | 11 | 2.67 (1.19 to 5.98) |
| >210-g/m2 anthracycline dose | 85 | 1.19 (0.92 to 1.55) | 45 | 1.29 (0.89 to 1.87) | 12 | 2.35 (1.12 to 4.94) |
| Procarbazine | ||||||
| No CT or no procarbazine | 251 | 1.00 (Ref.) | 205 | 1.00 (Ref.) | 22 | 1.0 (Ref.) |
| ≤4.2-g/m2 procarbazine dose | 81 | 1.09 (0.82 to 1.47) | 47 | 1.00 (0.69 to 1.45) | 11 | 0.91 (0.39 to 2.09) |
| >4.2-g/m2 procarbazine dose | 204 | 1.53 (1.26 to 1.85) | 86 | 0.87 (0.66 to 1.13) | 21 | 1.37 (0.74 to 2.53) |
a
Attained age was used as the primary x-axis in all models. CI = confidence interval; CT = chemotherapy; HL = Hodgkin lymphoma; HR = hazard ratio; RT = radiotherapy.
b
Excluding deaths from cerebrovascular disease. Model stratified for treatment period.
c
For variables with missing values, the number of patients in each category do not add up to the total number of patients. Missing values for each variable were assigned to a “missing” category and analyzed as such in the model. Hazard ratios for this category showed no statistical significance and are not presented in this table.